Therapeutic Vaccines Market
Every Market-Reports.com study delivers in-depth market sizing, growth forecasts, competitive intelligence, segmentation analysis, and regional insights — built from company filings, government statistics and trade data, and structured for confident strategic decision-making. Request a free report preview to see its scope, chapters and methodology before you buy.
Market Snapshot
2025 Market Size
US$ 6.2 billion
Estimated Base Value
2035 Forecast
US$ 18.7 billion
Projected Market Value
CAGR 2026–2035
11.7%
Compound Annual Growth
Largest Segment
Cancer Vaccines
Fastest Growing Segment
Electric Commercial Vehicles
Leading Region
Asia Pacific
Fastest Growing Region
Asia Pacific
Top Country
United States
By Market Share
Largest market
Key Players
BioNTech
Emerging Players
Nykode Therapeutics, IO Biotech
Therapeutic Vaccines Market Overview
The Therapeutic Vaccines Market focuses on pharmaceutical products designed to treat existing diseases by stimulating or enhancing a patient's immune response against specific pathological targets. These vaccines aim to mitigate disease progression, reduce symptoms, or achieve remission in individuals already afflicted, distinguishing them from prophylactic vaccines that prevent disease onset. The market includes advanced vaccine platforms and delivery systems targeting various cancers, chronic infectious diseases like HIV and hepatitis, and certain autoimmune disorders, serving as a critical component of the broader immunotherapeutics landscape. Buyers include hospitals, specialty clinics, academic and research institutions, contract research organizations, and ambulatory care settings.
The Therapeutic Vaccines Market is estimated at $6.2 Bn in 2025 and is forecast to reach $18.7 Bn by 2035, growing at a CAGR of 11.7% from 2025 to 2035. Demand is driven by the rising global burden of chronic and infectious diseases, an aging population requiring advanced therapeutic options, and improved efficacy and safety profiles compared to conventional therapies. Significant R&D investments and government support also contribute to market expansion. However, high R&D costs, lengthy development cycles, and strict regulatory approval processes present restraints to market growth.
The market is segmented by Type (Cancer Vaccines, Infectious Disease Vaccines, Autoimmune Disease Vaccines, Neurological Disorder Vaccines, Allergy & Asthma Vaccines, Addiction & Substance Abuse Vaccines, Metabolic Disorder Vaccines), Technology (Protein Subunit Vaccines, Recombinant Vector Vaccines, Dendritic Cell Vaccines, DNA Vaccines, Messenger RNA Vaccines, Viral Vector Vaccines, Whole-Cell Vaccines, Peptide Vaccines), End-User, Form, Process Stage, and Target Antigen. Geographically, the market is served across Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. Leading companies include BioNTech, Gritstone bio, CureVac, ImmunityBio, Agenus, Transgene, Hookipa Pharma, OSE Immunotherapeutics, PDS Biotechnology, Inovio Pharmaceuticals, VBI Vaccines, and Immunomic Therapeutics. The full report covers global market analysis, segmentation, market sizing and forecast from 2025 to 2035, and coverage of commercialized products and late-stage clinical pipeline candidates.
Market Definition & Overview
The Therapeutic Vaccines Market comprises pharmaceutical products engineered to treat existing diseases by stimulating or enhancing the patient's endogenous immune response against specific pathological targets. Unlike prophylactic vaccines, which prevent disease onset, therapeutic vaccines aim to mitigate disease progression, reduce symptoms, or achieve remission in individuals already afflicted. This market encompasses innovative vaccine platforms targeting various cancers, chronic infectious diseases such as HIV, hepatitis B, and hepatitis C, and certain autoimmune disorders. It includes advanced vaccine technologies and delivery systems designed to elicit potent and sustained immune responses, representing a crucial segment within the broader immunotherapeutics landscape.
Scope
- Global market analysis across key geographic regions.
- Segmentation by disease indication, vaccine technology, and end-user.
- Market sizing and forecast from 2025 to 2035.
- Coverage of commercialized products and late-stage clinical pipeline candidates.
Inclusions
- Therapeutic vaccines for various oncology indications.
- Therapeutic vaccines targeting chronic infectious diseases (e.g., HIV, HBV, HCV).
- DNA, RNA, viral vector, peptide, and dendritic cell vaccine platforms.
- Sales revenue from product manufacturing and distribution.
- Market analysis of approved therapeutic vaccines.
- Analysis of therapeutic vaccine candidates in Phase 3 clinical trials.
Exclusions
- Prophylactic (preventative) vaccines for infectious diseases.
- Conventional small molecule drugs or non-vaccine biologics.
- Diagnostic kits or services.
- Standalone gene therapies or cell therapies not utilizing vaccine principles.
- Early-stage research and discovery funding (pre-clinical and Phase 1/2 unless specifically projected for commercialization within forecast).
Market Size Forecast
Executive Summary
• The Therapeutic Vaccines market is valued at $6.2 Bn in 2025 and is forecast to reach $18.7 Bn by 2035, reflecting a robust CAGR of 11.7% as demand accelerates across every major segment and region over the ten-year outlook.
• Cancer Vaccines leads the segment breakdown by current market share, underscoring where the bulk of near-term revenue and competitive activity within this market is concentrated today.
• Asia Pacific commands the largest regional share at XX.X%, while Emerging Areas is expanding the fastest at a XX.X% CAGR, signalling where future growth is shifting.
• United States remains the single largest country-level market at XX.X% of global share, anchoring overall demand within its home region throughout the forecast period.
• The therapeutic vaccines market is experiencing increasing consolidation, driven by strategic M&A activities and targeted partnerships between big pharma and biotech innovators, aiming to acquire novel platform technologies and accelerate pipeline development, reshaping long-term competitive advantages.
• Growth is significantly fueled by the escalating prevalence of chronic diseases and the push towards personalized medicine approaches, complemented by evolving regulatory pathways that de-risk advanced therapy development and foster robust innovation globally.
• Technological breakthroughs in mRNA and viral vector platforms, alongside artificial intelligence applications, are fundamentally transforming vaccine development, enabling faster target identification and more precise immunomodulation, thereby expanding therapeutic applicability across diverse indications.
• Oncology remains the dominant segment, with significant investment in neoantigen and oncolytic virus therapies, while emerging economies present untapped potential for infectious disease vaccines due to rising healthcare infrastructure and disease burden.
• Significant capital influx from venture funding and pharmaceutical giants continues to propel R&D, particularly in late-stage clinical trials, while optimizing scalable manufacturing capabilities and global cold chain logistics remains a critical industry investment priority.
• The market’s long-term trajectory hinges on consistent clinical success and favorable reimbursement policies for novel therapies, navigating complex regulatory landscapes and patient access challenges to ensure sustainable commercialization globally.
Key Market Takeaways
Critical findings and data points from this market research study.
Future Market Growth
The market is projected to reach $18.7 billion by the forecast year.
Strong Growth Trajectory
This indicates a significant compound annual growth rate (CAGR) of 11.7% during the forecast period.
Oncology Segment Leadership
Therapeutic vaccines targeting oncology are anticipated to maintain their position as a leading segment within the market.
Personalized Medicine Trend
The increasing emphasis on personalized medicine and advanced biotechnological approaches is a key trend driving market innovation.
Robust Market Outlook
The substantial growth from $6.2 billion to $18.7 billion reflects growing investments and a high demand for innovative therapeutic solutions.
Market Dynamics
Market Trends
- Increasing adoption of personalized cancer immunotherapies.
- mRNA and DNA vaccine platforms are gaining traction.
- Growing research into therapeutic vaccines for autoimmune diseases.
- Combination therapies with checkpoint inhibitors are becoming prevalent.
Growth Drivers
- Rising global burden of chronic and infectious diseases.
- Aging population fuels demand for advanced therapeutic options.
- Improved efficacy and safety profiles compared to conventional therapies.
- Significant R&D investments and government support drive innovation.
Restraints
- High R&D costs and lengthy development cycles impede market growth.
- Strict regulatory approval processes create significant market entry barriers.
- Variable efficacy across diverse diseases remains a key therapeutic challenge.
- Intense competition from established treatments limits market penetration.
Opportunities
- Development of vaccines for neglected and rare diseases.
- Expanding applications to non-infectious conditions like Alzheimer's.
- Emerging economies present substantial growth opportunities.
- Technological advancements enable novel and more effective vaccine designs.
Market Dynamics Framework · 2026–2035
Need Custom Data for This Market?
Get tailored segmentation, deeper competitive intelligence, or region-specific deep dives from our analyst team.
Market Segmentation
| Segment | Sub-segments |
|---|---|
| By Type | Cancer VaccinesInfectious Disease VaccinesAutoimmune Disease VaccinesNeurological Disorder VaccinesAllergy & Asthma VaccinesAddiction & Substance Abuse VaccinesMetabolic Disorder Vaccines |
| By Technology | Protein Subunit VaccinesRecombinant Vector VaccinesDendritic Cell VaccinesDNA VaccinesMessenger RNA VaccinesViral Vector VaccinesWhole-Cell VaccinesPeptide Vaccines |
| By End-User | HospitalsSpecialty Clinics & CentersAcademic & Research InstitutionsContract Research OrganizationsAmbulatory Care Settings |
| By Form | Injectable SuspensionsInjectable SolutionsLyophilized Powders for ReconstitutionOral FormulationsTransdermal PatchesNasal Sprays |
| By Process Stage | Pre-Clinical DevelopmentClinical Trials Phase IClinical Trials Phase IIClinical Trials Phase IIICommercial ManufacturingRegulatory Affairs & Post-Market Surveillance |
| By Target Antigen | Tumor AntigensViral AntigensBacterial AntigensAutoantigensAllergen AntigensAddiction Target AntigensOther Antigens |
Regional Analysis
- North America leads the therapeutic vaccines market due to substantial R&D investments, the presence of major pharmaceutical companies, and robust healthcare infrastructure. Its advanced regulatory framework and high patient awareness also significantly contribute to market dominance in this specialized sector.
- Asia-Pacific is projected to be the fastest-growing region, driven by increasing healthcare expenditure, a large patient pool, and the rising prevalence of chronic diseases like cancer. Enhanced R&D activities and growing government support for healthcare innovation further propel market expansion.
- Europe is witnessing a notable trend towards precision medicine and personalized therapeutic vaccines, driven by strong academic research and significant government funding. Collaborative initiatives between biotech firms and research institutions are accelerating the development of targeted therapies for various chronic conditions.
| Asia PacificXX.X% | North AmericaXX.X% | EuropeXX.X% | Latin AmericaXX.X% | Middle East & AfricaXX.X% |
North America
XX.X% CAGR
US$ XX.X Mn
XX.X% share
- Characterized by significant R&D activities, presence of major pharmaceutical companies, and advanced healthcare infrastructure.
- High awareness of preventive healthcare and favorable regulatory frameworks contribute to its stable growth.
Latin America
XX.X% CAGR
US$ XX.X Mn
XX.X% share
- Exhibits strong growth potential due to increasing healthcare expenditure, improving access to advanced medical treatments, and a rising incidence of infectious diseases and certain cancers.
- Government efforts to expand vaccination programs are also impactful.
Europe
XX.X% CAGR
US$ XX.X Mn
XX.X% share
- Benefits from robust research funding, a well-established pharmaceutical industry, and an aging population prone to chronic diseases requiring therapeutic interventions.
- Regulatory support for innovation and strong public health programs are key drivers.
Asia Pacific
XX.X% CAGR
US$ XX.X Mn
XX.X% share
- Driven by rising prevalence of chronic diseases, expanding healthcare infrastructure, and growing R&D investments in countries like China and India.
- Government initiatives supporting vaccine development and access further boost market expansion.
Middle East & Africa
XX.X% CAGR
US$ XX.X Mn
XX.X% share
- Poised for growth with increasing healthcare investments, a rising burden of infectious diseases, and improving healthcare infrastructure in key countries.
- Efforts to enhance public health and diversify economies are stimulating market development.
Country Analysis
United States and Brazil represent the largest country-level markets, with growth across the remaining countries shaped by local regulatory, infrastructure, and demand-side factors specific to each geography.
| # | Country | Market Size | CAGR | Key Driver |
|---|---|---|---|---|
| 1 | United States | US$ XX.X Mn | XX.X% | The U.S. leads the therapeutic vaccines market due to extensive R&D investments, advanced biotechnology infrastructure, high healthcare spending, and a large patient population driving demand for novel treatments. |
| 2 | Brazil | US$ XX.X Mn | XX.X% | Brazil is a key South American market owing to its large population, significant burden of infectious and chronic diseases, and a developing biotech sector supported by public health programs. |
| 3 | Germany | US$ XX.X Mn | XX.X% | Germany's robust pharmaceutical industry, high R&D expenditure, excellent healthcare infrastructure, and leading research institutions make it a major player in therapeutic vaccine development and adoption. |
| 4 | China | US$ XX.X Mn | XX.X% | China is a critical market due to its immense patient population, rapidly increasing healthcare spending, substantial government investment in biotech R&D, and growing domestic vaccine innovation. |
| 5 | Saudi Arabia | US$ XX.X Mn | XX.X% | Saudi Arabia is a prominent market in the Middle East due to high healthcare spending, strategic initiatives to diversify into biotechnology, and an increasing focus on advanced disease management. |
Countries Covered (26)
United States, Canada, Mexico, Brazil, Argentina, Rest of Latin America, Germany, United Kingdom, France, Italy, Spain, Russia, Rest of Europe, China, Japan, India, South Korea, Australia, Taiwan, Singapore, Malaysia, Rest of Asia Pacific, Saudi Arabia, South Africa, United Arab Emirates, Rest of Middle East & Africa
Competitive Landscape
| # | Company | Share | Key Strategy | Key Note | Key Developments | Key Products |
|---|---|---|---|---|---|---|
| 1 | BioNTech | XX.X% | Leveraging mRNA technology across multiple therapeutic areas, including infectious diseases and oncology, to develop highly targeted and effective immunotherapies. | — | — | ComirnatyBNT111BNT112+1 |
| 2 | Gritstone bio | XX.X% | Developing personalized and off-the-shelf cancer immunotherapies using an adenovirus-based vector platform and neoantigen targeting. | — | — | GRANITESLATEOBSIDIAN |
| 3 | CureVac | XX.X% | Advancing a diverse pipeline of mRNA-based vaccines and therapeutics, focusing on both infectious diseases and oncology, using its proprietary mRNA backbone. | — | — | CV8102CV7202CV0501 |
| 4 | ImmunityBio | XX.X% | Developing a comprehensive 'cancer vaccine' approach that combines multiple immunotherapy modalities, including cell therapies, oncolytic viruses, and therapeutic vaccines. | — | — | AnktivaN-803hAd5-CEA-PADRE |
| 5 | Agenus | XX.X% | Developing a portfolio of immuno-oncology agents, including checkpoint inhibitors, therapeutic vaccines, and novel antibodies, to address unmet needs in cancer treatment. | — | — | BotensilimabBalstilimabAGEN1181+1 |
Market Positioning Map
Market share vs. growth outlook — bubble size is market share, bubble color is relative profitability
Companies Profiled (20)
BioNTech, Gritstone bio, CureVac, ImmunityBio, Agenus, Transgene, Hookipa Pharma, OSE Immunotherapeutics, PDS Biotechnology, Inovio Pharmaceuticals, VBI Vaccines, Immunomic Therapeutics, Elicio Therapeutics, Advaxis, NightHawk Biosciences, Sensei Biotherapeutics, Evaxion Biotech, IMVX Pharmaceuticals, Emergex Vaccines, NeoVax, Inc.
The global Therapeutic Vaccines market features a competitive landscape led by BioNTech, Gritstone bio, CureVac, ImmunityBio, Agenus, and Transgene, among other established and emerging players. Market participants continue to compete on product innovation, pricing strategy, geographic expansion, and strategic partnerships to strengthen their position in this evolving market.
* Market share estimates based on company revenue disclosures and public sources; undisclosed figures are marked.
Company Profiles
BioNTech
Gritstone bio
CureVac
ImmunityBio
Agenus
Transgene
Hookipa Pharma
OSE Immunotherapeutics
PDS Biotechnology
Inovio Pharmaceuticals
VBI Vaccines
Immunomic Therapeutics
Elicio Therapeutics
Advaxis
NightHawk Biosciences
Sensei Biotherapeutics
Evaxion Biotech
IMVX Pharmaceuticals
Emergex Vaccines
NeoVax, Inc.
* Classification reflects relative market share and maturity, derived from revenue analysis and public disclosures.
Ready to Make Data-Driven Decisions?
Purchase the full report or request a custom engagement. Get analyst support, scenario modelling, and real-time dashboard access.
Recent Market Developments
Novel Personalized Cancer Vaccine Receives Accelerated FDA Approval
A leading biotech firm secured accelerated FDA approval for its individualized mRNA-based therapeutic cancer vaccine, targeting specific neoantigens in advanced melanoma patients. This breakthrough offers a new frontier in personalized immuno-oncology treatments.
Global Pharma Forms Strategic Partnership for Chronic HBV Therapeutic Vaccine
A major pharmaceutical company announced a strategic collaboration with a specialized biotech firm to co-develop and commercialize a next-generation therapeutic vaccine designed to achieve a functional cure for chronic Hepatitis B virus (HBV) infection. The partnership will focus on novel antigen delivery platforms.
Therapeutic Vaccine Startup Secures US$ XX.X Series C for Autoimmune Pipeline
An emerging therapeutic vaccine company focused on autoimmune diseases successfully closed a US$ XX.X Series C funding round. The investment will primarily advance its lead candidate, a therapeutic vaccine for rheumatoid arthritis, into later-stage clinical trials.
Big Pharma Acquires Innovator of Advanced mRNA Delivery Platform
A global pharmaceutical giant completed the acquisition of a cutting-edge biotech company renowned for its proprietary mRNA delivery platform technology. This strategic move aims to significantly enhance the acquirer's therapeutic vaccine pipeline across oncology and infectious diseases.
Report Data Parameters
| Parameter | Value |
|---|---|
| Base Year | 2025 |
| Forecast Year | 2035 |
| Historical Period | 2019–2025 |
| Market Size (Base Year) | $6.2 Bn |
| Market Size (Forecast) | $18.7 Bn |
| CAGR | 11.7% |
| Forecast Period | 2026–2035 |
| Geography | Global |
| Countries Covered | 26 Countries |
| Segments Covered | 6 Segments, 39 Sub-segments |
| Companies Profiled | 32 Companies |
Report Value
Why Choose This Report
Complete Market Size
Market sizing for the base year and a 10-year forecast across three scenarios.
Segment Analysis
Deep-dive segmentation by product, application, end-user, and technology verticals.
Country Analysis
Country-level market data for every country in the report scope, across all major regions.
Company Profiles
Profiles of the leading companies, with disclosed financials, strategy and market share.
Market Share
Detailed competitive market share analysis with trend mapping and benchmarking.
Competitive Intelligence
SWOT, Porter's Five Forces, and competitive positioning across market leaders.
Scenario Analysis
Three-scenario modelling (Base / Optimistic / Conservative) with CAGR decomposition.
Regulatory Review
Regulatory landscape, compliance requirements, and policy impact analysis by region.
Strategic Analysis · Management Insights · CXO Insights
Executive Strategic & Intelligence Report
A board-ready strategic deck built on the Therapeutic Vaccines Market report: eleven chapters and an appendix, from market sizing to the board decisions, delivered as a PDF with an Excel datapack. US$3,000 per market, prepared after your order.
What to expect in the Executive Report for this market
- About 400 slides, 11 chapters and an appendix. Built on this report's own numbers, so every figure matches the report and the Excel.
- Market size and forecast to 2035. By segment, sub-segment, region and country, with conservative, base and optimistic cases.
- An analysis page after every exhibit. The key insight, ten specific points and the decision it implies for leaders, challengers, entrants and investors.
- Competitive intelligence. Shares and positioning, capability benchmark, strategies, recent moves and acquisition screening.
- Customers, technology and business models. Who buys and why, AI and technology impact, pricing, channels and go-to-market by segment.
- Risks and scenarios. Risk register, four future scenarios with signposts, and early-warning indicators with thresholds.
- Opportunities and the board decisions. Opportunity scoring, strategic options, roadmap, capability gaps, decision matrix and a 90-day plan.
- PDF, Excel datapack and PowerPoint. A bookmarked PDF, the full Excel datapack and editable infographic slides for your own decks.
US$3,000 per market · bought online, prepared after your order and emailed to you
See a full example report →Only need the headline view? Market Snapshot (PDF) + Excel Datasheet · 10–20 slide PDF + Excel
A CEO-level executive summary of the market in 10–20 slides - size and forecast, growth by segment and region, the leading countries and companies, key trends and the outlook - plus the Excel datasheet. A short executive view of this market, not the full analysis - PDF and Excel, prepared and emailed to you after your order.
Trusted by strategy teams, investors & global enterprises
What Our Clients Say
Verified reviews from enterprise clients
“The depth of analysis and quality of data is unparalleled. This report directly informed our $50M market expansion strategy and helped us prioritise the right geographies.”
Sarah Chen
VP Strategy, Fortune 500 Manufacturer
“Exceptional research quality. The competitive landscape section alone saved our team months of primary research effort and gave us a clear view of the opportunity.”
Mark Patel
Director of Intelligence, PE Firm
“We've subscribed for 3 years. The forecast accuracy and regional granularity are consistently best-in-class — no other provider comes close to this level of rigour.”
Lena Hoffmann
Head of Market Intelligence, Industrial MNC
Frequently Asked Questions
Common questions about this report and our research
The Therapeutic Vaccines Market is estimated at $6.2 Bn in 2025. It is forecast to reach $18.7 Bn by 2035.
The Therapeutic Vaccines Market is forecast to grow at a CAGR of 11.7% from 2025 to 2035.
The main segments are by Type (Cancer Vaccines, Infectious Disease Vaccines, Autoimmune Disease Vaccines), Technology (Protein Subunit Vaccines, Recombinant Vector Vaccines, Dendritic Cell Vaccines), End-User, Form, Process Stage, and Target Antigen.
Leading companies include BioNTech, Gritstone bio, CureVac, ImmunityBio, Agenus, Transgene, Hookipa Pharma, OSE Immunotherapeutics, PDS Biotechnology, Inovio Pharmaceuticals, VBI Vaccines, and Immunomic Therapeutics.
The report covers global market analysis across key geographic regions, segmentation by disease indication, vaccine technology, and end-user. It provides market sizing and forecast from 2025 to 2035, and covers commercialized products and late-stage clinical pipeline candidates.
The Single User and Enterprise licences include the full PDF report, the PowerPoint (PPT), the Excel data workbook and the interactive Online Dashboard. The Online Dashboard gives online access to the snapshot and datasheet with export features, and the Market Snapshot is an executive summary in PDF with the Excel data sheet.
Yes. Request a free report preview: its scope, every chapter and what it contains, the methodology and the headline figures. The full report is a paid product.
We accept credit/debit cards (Visa, Mastercard, Amex), bank wire transfer, and purchase orders for enterprise clients. All transactions are secured with 256-bit SSL encryption.
Buy This Report
Choose the format that fits your budget
Digital delivery — all sales are final. See our Refund Policy and Terms & Conditions.
Strategic deck for this market
Executive Strategic & Intelligence Report
About 400 board-ready slides: every exhibit with its analysis and the decision it implies. Prepared for this market after your order and emailed to you.
Need to go deeper?
Intelligence services for this market
- Competitor benchmarking →
- Market entry & expansion →
- Product & growth opportunities →
- Investment & acquisition due diligence →
What's Included
Similar Reports
DNA Vaccines Market
$228.0 Mn in 2025 · 24.9% CAGR
Personalized Cancer Vaccines Market
$416.0 Mn in 2025 · 29.0% CAGR
Respiratory Vaccines Market
$19.0 Bn in 2025 · 7.8% CAGR
RNA Vaccines Market
$19.7 Bn in 2025 · 8.6% CAGR
Digital Therapeutic Manufacturing Market
$284.0 Mn in 2025 · 18.9% CAGR
Advanced Cell Manufacturing Market
$8.9 Bn in 2025 · 15.9% CAGR
AI Bioengineering Market
$2.7 Bn in 2025 · 25.5% CAGR
AI Bioinformatics Platform Market
$1.7 Bn in 2025 · 22.8% CAGR